摘要
目的评价雷贝拉唑联合枸橼酸铋钾治疗幽门螺杆菌（Hp）感染活动性消化性溃疡（PU）的临床疗效、安全性及复发率。方法将160例消化性溃疡患者分为治疗组和对照组（各80例）。治疗组予以雷贝拉唑＋枸橼酸铋钾＋阿莫西林克拉维酸钾十呋喃唑酮四联方案，共7天，继予雷贝拉唑＋硫糖铝抗溃疡治疗，十二指肠溃疡患者疗程4周，胃溃疡患者疗程8周。对照组予奥美拉唑＋阿莫西林克拉维酸钾＋呋喃唑酮三联方案，共7天，继予奥美拉唑＋硫糖铝抗溃疡治疗，十二指肠溃疡患者疗程4周，胃溃疡患者疗程8周。完成全疗程4周后复查14C-尿素呼气试验及胃镜检查。结果两组患者治疗1周后，症状改善显效率均达到95．00％以上；治疗组Hp根治率为95．00％，对照组为81．25％，两组比较差异有统计学意义（P〈0．01）；治疗组溃疡总愈合率为93．75％，对照组为78．75％，两组比较差异有统计学意义（P〈0．01）；两组不良反应发生率均较低，两组比较差异无统计学意义（P〉0．05）；治疗组1年随访消化性溃疡复发率和Hp复阳率分别为8．86％和12．66％，对照组分别为27．40％和35．62％，两组比较差异均有统计学意义（P〈0．01）。结论雷贝拉唑联合枸橼酸铋钾方案治疗活动性消化性溃疡能迅速控制临床症状，促进溃疡早期愈合，具有Hp根治率高，不良反应少，疗效可靠的特点。
Objective To evaluate the clinical effects, safety and relapse rate of rabeprazole and bismuth potassium citrate on active peptic ulcer（PU） with helicobacter pylori （Hp） infection. Methods 160 PU cases were randomly divided into treatment group and control group. Treatment group was treated with four joint programme（ rabeprazole ＋ bismuth potassium citrate ＋ amoxicillin clavulanic potassium ＋ fnran thiazole ketone）7 days for eradicating Hp;followed by rabeprazole and sucralfate to treat duodenal ulcer（DU） for 4 weeks and gastric ulcer（GU） for 8 weeks. Control group was treated with three joint pro- gramme（ omeprazole ＋ amoxicillin clavulanic potassium ＋ furan thiazole ketone）7 days for eradicating HP; followed by omeprazole and sucralfate to treat DU for 4 weeks and GU for 8 weeks. 14 C-urea breath test and gastroscope inspection were carried out 4 weeks later after the treatment. Results After 1 week treatment in 2 groups,the symptom improving efficiency rate were all more than 95.00% ;the Hp eradica- tion rate was 95.00% in the ＇treatment group,81.25 % in the control group,The diffenrence between them was significant（P 〈 0.01 ） ;the total ulcer healing rate in the treatment group was 93.75% , and 78.75% in control group （P 〈 0.01 ） ;the incidence rate of side effects in 2 groups was low （P 〉 0.05 ） ;1-year fol- low-up PU relapse rate and Hp relapse positive rate of the treatment group was 8.86% and 12.66% ,but 27.40% and 35.62% in control group, the differences were significant （P 〈 0.01 ）. Conclusion The treatment of active PU combined rabeprazole with bismuth potassium citrate can quickly control clinical symptoms, promote healing in early stage of the ulcer, and has high Hp eradication rate, and it is also safe and reliable.
出处
《临床内科杂志》
CAS
2012年第7期478-481,共4页
Journal of Clinical Internal Medicine
关键词
雷贝拉唑钠
质子泵抑制剂
枸橼酸铋钾
消化性溃疡
Rabeprazole sodium, Proton pump inhibitors
Bismuth potassium citrate
Peptic ulcer
